Cue Biopharma
50 hedge funds and large institutions have $10.5M invested in Cue Biopharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
89% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 28
Holders
50
Holding in Top 10
–
Calls
$24K
Puts
$8K
Top Buyers
| 1 | +$1.62M | |
| 2 | +$102K | |
| 3 | +$56.8K | |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$20.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.4K |
Top Sellers
| 1 | -$314K | |
| 2 | -$191K | |
| 3 | -$188K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$161K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$149K |